Sandoz
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in offering high-quality and low-cost pharmaceutical products no longer protected by patents. In additional to developing and marketing generic drugs, Sandoz is a leading manufacturer of antiinfectives and active substances for other pharmaceutical and biotechnology products.
Sandoz also is committed to a key growth area of creating follow-on versions of biotechnology medicines that have lost patent protection, enabling significant cost savings for society.
Novartis is the only major pharmaceutical company to achieve leadership positions in both patented prescription drugs and generic pharmaceuticals. Sandoz plays an increasingly important role in our strategy of offering a range of medicines to patients, physicians and healthcare providers worldwide.
The key product groups of Sandoz include antibiotics, treatments for central-nervous-system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies.
Company history
Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz.